DiagnosTear Technologies Inc. Announces Upsizing of Private Placement of Units

Executive Summary

• DiagnosTear Technologies Inc. increased its previously announced non‑brokered private placement to up to 2,000,000 units at $0.50 per unit, targeting aggregate gross proceeds of $1,000,000.
• Each unit consists of one common share and one warrant exercisable at $1.00 per share for a term of 18 months.
• Net proceeds will be used for working capital and general corporate purposes; closing expected on or before November 5, 2025.

Key Details

• Offering Size: Up to 2,000,000 units (previously announced amount increased).
• Price per Unit: $0.50 → total gross proceeds of $1,000,000.
• Unit Composition: 1 common share + 1 warrant.
• Warrant Terms: Exercise price $1.00; exercisable for 18 months from closing date.
• Use of Proceeds: Working capital and general corporate purposes.
• Closing Date: Anticipated on or before November 5, 2025 (subject to receipt of documentation, funds, and CSE compliance).
• Statutory Hold Period: Securities subject to a hold period expiring four months and one day after issuance.
• Regulatory Notes: No finder's fees; securities not registered under U.S. securities laws and may not be offered/sold in the United States absent exemption or registration.

Notable Quotes

(No direct quotes were provided in the release.)